Die Onkologie pp 711-727 | Cite as

Medikamentöse Schmerztherapie in der Onkologie

  • B. Fazeny-Dörner
  • C. Dittrich

Zusammenfassung

Wie bei keiner anderen Krankheit wird bei Tumorpatienten der Schmerz zum Signal des unaufhaltsamen Fortschreitens der lebensbedrohenden Erkrankung und zählt zu den häufigsten und am meisten gefürchteten Symptomen (Bonica 1985; Coyle et al. 1990). Zahlreiche Übersichtsarbeiten haben gezeigt, dass 30–50% der Patienten bei Diagnosestellung und 60–90% der Patienten mit fortgeschrittener Tumorerkrankung an Dauerschmerzen leiden (Daut et al.1982; Foley 1979; Levin et al.1985;Twycross et al.1982; World Health Organization 1996).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahmedzai S, Brooks D (1997) Transdermal Fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of Iife. J Pain Sympt Manage 5: 254–261Google Scholar
  2. American College of Physicians Health and Public Committee (1983) Drug therapy for severe chronic pain in terminal illness.Ann Intern Med 99: 870Google Scholar
  3. Angarola RT,Wray SD (1989) Legal impediments to cancer pain treatment. In: Hill CS, Fields WS (eds) Advances in pain research and therapy, vol 11. Raven Press, New York, p 213Google Scholar
  4. Bach V, Kamp-Jensen M, Jensen N-H, Eriksen J (1991) Buprenorphine and sustained release morphine–effect and side-effects in chronic use. Pain Clinic 4: 87–93Google Scholar
  5. Bailey PL, Stanley TH (1994) Intravenous opioid Anesthetics. In: Miller RD (ed) Anesthesia, 4th edn. Churchill Livingstone, New York, pp 291–387Google Scholar
  6. Bajwa ZH.Borsook D (1996) The pain management imperative. In: Borsook D, LeBel AA, McPeek B (eds) The Massachusetts General Hospital handbook of pain management. Little, Brown and Company, Boston New York Toronto London Little, pp 3–7Google Scholar
  7. Beaver WT (1988) Impact of non-narcotic analgesics on pain management. Am J Med 84: 3–15PubMedGoogle Scholar
  8. Berina LF, Guernsey BG, Hokanson JA, Doutre WH, Fuller LE (1985) Physician perception of a triplicate prescription law. Am J Hosp Pharm 42: 857Google Scholar
  9. Berkowitz BA, Ngai SH,Yang JC (1975) The disposition of morphine in surgical patients. Clin Pharmacol Ther 17: 629–635Google Scholar
  10. Bonica JJ (1977) Neurophysiologic and pathologic aspects of acute and chronic pain. Arch Surg 112: 750–761PubMedGoogle Scholar
  11. Bonica JJ (1979) Important clinical aspects of acute and chronic pain. In: Mechanisms of pain and analgesic compounds.ln: Beers RF, Bassett EG (eds) Raven Press, New York, pp 15–29Google Scholar
  12. Bonica JJ (1985) Treatment of cancer pain: current status and future need. In:Fields HL, Dubner R,Cervero R (eds) Advances in pain research and therapy, vol 9. Raven Press, New York, pp 617–628Google Scholar
  13. Bonica JJ (1990) Cancer pain.ln:Bonica JJ (ed)The management of pain. Lea Febiger, Philadelphia, p 400Google Scholar
  14. Breitbart W, Holland JC (1988) Psychiatric complications of cancer. Curr Ther Hematol Oncol 3: 268Google Scholar
  15. Bruera E, Roca E,Cedaro L,Carrao S,Chacon R (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double blind study. Cancer Treat Rep 69: 751–754Google Scholar
  16. Bruera E, Fainsinger R, Spachynski K (1995) Clinical efficacy and safety of a novel controlled release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol 13: 1520–1527PubMedGoogle Scholar
  17. Brune K, Beck WS (1993) Nichtopioidanalgetika. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft,Stuttgart,S 121–136Google Scholar
  18. Campora E, Merlini L, Pace M, Bruzzone M, Luzzani M, Gottlieb A, Rosso R (1991) The incidence of narcotic induced emesis. J Pain Symptom Manage 6: 428–430PubMedGoogle Scholar
  19. Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen. Eigenschaften von Nichtopioiden und Opioiden. Schmerz 8: 195–209PubMedGoogle Scholar
  20. Cherny NI, Portenoy RK, Raber M, Zenz M (1995) Medikamentöse Therapie von Tumorschmerzen.Teil Ill: Adjuvantien. Schmerz 9: 55–69PubMedGoogle Scholar
  21. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya IO (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330: 592–596PubMedGoogle Scholar
  22. Cleeland CS, Cleeland LM, Dar R, Rinehardt LC (1986) Factors influencing physican management of cancer pain. Cancer 58: 796–800PubMedGoogle Scholar
  23. Cooper K, Bennet W (1987) Nephrotoxicity of common drugs used in clinical practice. Arch Intern Med 147: 1213–1218PubMedGoogle Scholar
  24. Coyle N,AdelhardtJ,Foley KM, Portenoy RK (1990) Character of terminal illness in the advanced cancer patient:pain and other symptoms during the last four weeks of life.J Pain Symptom Manage 5: 83–93Google Scholar
  25. Dar R, Beach C, Barden P, Cleeland CS (1992) Cancer pain in the marital system: a study of patients and spouses. J Pain Symptom Manage 7: 87–93PubMedGoogle Scholar
  26. Daut RL, Cleeland CS (1982) The prevalence and severity of pain in cancer. Cancer 50: 1913–1918PubMedGoogle Scholar
  27. DeConno, Ripamonti C, Saita L (1995) The role of the rectal route in treating cancer pain: a randomized crossover clinical trial of oral vs. rectal morphine administration of opioid-naive cancer patients with pain.J Clin Oncol 13: 1004–1008Google Scholar
  28. Devor M, Govrin-lippman R, Raber P (1985) Corticosteroids reduce neuro-ma hyperexcitability. In: Fields HL, Dubner R, Crevero F (eds) Proceedings of the Fourth World Congress on Pain. Advances in pain research and therapy, vol 9. Raven Press, New York, p 451Google Scholar
  29. Dittrich C (1996) Strategie der Schmerztherapie/Schmerzkontrolle bei Patienten mit Malignomen. Hausarzt 6: 6–13Google Scholar
  30. Doyle D (1991) Morphin: myths, morality and economics. Postgrad Med J 67 [Suppl 21: 70Google Scholar
  31. Elliot F, Little A,Milbrandt W (1976) Carbamazepine for phantom limb phenomena. N Engl J Med 295: 678Google Scholar
  32. Elliott TE, Murray DM, Oken MM, Johnson KM, Braun BL, Elliott BA, Post-White J (1997) Improving cancer pain mangement in communities: main results from a randomized controlled trial.J Pain Symptom Manage 13: 191–203Google Scholar
  33. Fainsinger R, Schoeller T, Bruera E (1993) Methadone in the management of cancer pain:a review. Pain 52: 137–147PubMedGoogle Scholar
  34. Fazeny B, Huber H (2000) Der Wunsch nach assistiertem Selbstmord bei unheilbaren Krebspatienten–Eine Standortbestimmung der Hauptursachen für die zunehmenden Diskussionen. In: Bonelli J, Prat EH (Hrsg) Leben–Sterben–Euthanasie? Springer, Wien New York, pp 97–102Google Scholar
  35. Fazeny B, Muhm M, Hauser I et al. (2000) Barriers in cancer pain management. Wien Klin Wochenschr 112: 987–981Google Scholar
  36. Fazeny B, Muhm M, Berzlanovich A, Wenzel C, Hagmeister H, Marosi Ch (2000) Schmerztherapie im Lichte rezenter Gesetzesnovellierungen und deren praktische Konsequenzen. Wien Klin Wochenschr 112: 372–375PubMedGoogle Scholar
  37. Foldes FF, Sverdlow M, Siker ES (1964) Narcotics and Narcotic Antagonists. Charles C Thomas, Springfield, ILGoogle Scholar
  38. Foley KM (1979) Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy. Raven Press, New York, pp 59–75Google Scholar
  39. Foley KM (1985) The treatment of cancer pain. N Engl J Med 313: 84–95PubMedGoogle Scholar
  40. Foley KM (1991) Clinical tolerance to opioids. In: Basbaum AI, Bessom JM (eds) Towards a new pharmacotherapy of pain, Dahlem Konferenzen. John Wiley Sons,Chinchester, p 181Google Scholar
  41. Foley KM (1993) Management of cancer pain. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles Practice ofOncology,4th edn. JB Lippincott, Philadelphia, pp 2417–2448Google Scholar
  42. Foley KM (1996) Pain relief into practice:rhetoric without reform.J Clin On-col 13: 2149–2151Google Scholar
  43. Foley KM, Inturrisi CE (1987) Analgesic drug therapy in cancer pain: Principles and practice. Med Clin North Am 72: 207–232Google Scholar
  44. Forth W, Henschler D, Rummel W, Starke K (1992) Pharmakologie und Toxikologie. B. I. Wissenschaftsverlag, MannheimGoogle Scholar
  45. Fromm GH (1989)Trigeminal neuralgia and related disorders. In: Portenoy RK (ed) Pain:Mechanisms and syndromes. Neruologic clinics,vol 7. WB Saunders, Philadelphia, p 305Google Scholar
  46. Gonzales GR, Elliott KJ, Portenoy RK, Foley KM (1991) Impact of a comprehensive evaluation in the management of cancer pain. Pain 47: 141–144PubMedGoogle Scholar
  47. Green WR, David WH (1991) Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. South Med J 84: 332–337Google Scholar
  48. Grond S, Zech D, Dahlmann H, Schug SA, Stobbe B, Lehmann KA (1990) Uberweisungsgrund:,,therapieresistente“ Tumorschmerzen. Analyse der Schmerzmechanismen und der medikamentösen Vorbehand1 u ng. Schmerz 4: 193–200PubMedGoogle Scholar
  49. Hanks GW,Twycross RG (1984) Pain, the physiological antagonist of opioid analgesics. Lancet 1: 1477–1478Google Scholar
  50. Hanks GW, Justins D (1992) Cancer pain: management. Lancet 339: 1031–1036PubMedGoogle Scholar
  51. Hanks GW,Twycross RG, Lloyd JW (1981) Unexpected complication of successful nerveblock. Anaesthesia 36: 37–39Google Scholar
  52. Hanks GW,Trueman T,Twycross RG (1983) Corticoids in terminal cancer. Postgrad Med J 59: 702Google Scholar
  53. Hayward J (1979) Psychological and social aspects of pain. Nursing 1: 1–7Google Scholar
  54. Hodes R (1989) Cancer patients’ needs and concerns when using narcotic analgesics. In: Hill CS, Fields WS (eds) Advances in pain research and therapy, vol 11. Raven Press, New York, pp 91–94Google Scholar
  55. Houde RW (1982) Methods for measuring clinical pain in humans. Acta Anesthesiol Scand [Suppl] 74: 25–20Google Scholar
  56. Hsieh JC, Carr D (1996) Choosing a therapeutic approach: opioids. In: Borsook D, LeBel AA, McPeek B (eds) The Massachusetts General Hospital handbook of pain management. Little, Brown and Company, Boston New York Toronto London pp 47–75Google Scholar
  57. Insel PA (1990) Analgesic antipyretics and antiinflammatory agents. Drugs employed in the treatment of rheumatic arthritis and gout. In: Gillan AG, RaIITW,Teylor P (eds) The pharmacologic basis oftherapeutics,8th edn. Pergamon Press, New York, p 638Google Scholar
  58. Inturrisi CE (1989) Management of cancer pain. Cancer 63: 2308–2320PubMedGoogle Scholar
  59. Jacox A, Carr DB, Payne R (1994) New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 330: 651–655PubMedGoogle Scholar
  60. Jaffe JH, Martin WR (1990) Opioid analgesics and antagonists. In: Gillamn AG, Rall TW, Nies AS,Teylor P (eds) The pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York, p 485Google Scholar
  61. Jage J (1990) Morphin-Mythos - Ausführungen zur Opiat-Analgesie. Med Welt 41: 92Google Scholar
  62. Jaksch W (1 996) Analgetika bei akuten Schmerzen. pm-Verlag, KössenGoogle Scholar
  63. Jurna I, Motsch J (1993a) Nichtanalgetika: Antidepressiva, Antikonvulsiva, Neuroleptika, Tranquilanzien und zentrale Muskelrelaxanzien, Clonidin,Cortison.In:Zenz M,Jurna I (Hrsg) Lehrbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 155–165Google Scholar
  64. Jurna I, BaldaufJ (1993b) Retardiert freigesetztes Naloxon oral:Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie.Schmerz 7: 314–321Google Scholar
  65. Jurna I, Spohrer B, Bock R (1992) Intrathecal injection of salicylic acid. Salicylic acid and indomethacine depress c-fibre evoked activity in the rat thalamus and spinal cord. Pain 49: 249–255PubMedGoogle Scholar
  66. Kanner RM, Foley KM (1981) Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 362: 161–172PubMedGoogle Scholar
  67. Kaufman PN, Krevsky B,Malmud LS, Maurer AH, Somers MB, Siegel JA, Fisher RS (1988) Role of opiate receptors in the regulation of colonic transit. Gastroenterology 94: 1351–1356Google Scholar
  68. Kloke M (1995) Therapie chronischer Tumorschmerzen. In: Therapiekonzepte Onkologie.Seeber S, Schütte J (Hrsg) Springer, Berlin Heidelberg NewYork,Tokyo,S 1092–1113Google Scholar
  69. Kloke M, Höffken K, Olbrich H, Schmidt CG (1991) Antidepressants and anticonvulsants for the treatment of neuropathic pain-syndromes in cancer patients. Oncology 14: 40–43Google Scholar
  70. Kuhar MJ, Pert CB, Snyder SH (1973) Regional distribution of opiate receptor binding in monkey and human brain. Nature 245: 447–450PubMedGoogle Scholar
  71. Leiberman A (1977) Use of high-dose corticosteroids in patients with inoperable brain tumors.J Neurol Neurosurg Psychiatry 40: 678Google Scholar
  72. Levin D, Cleeland CS, Dar R (1985) Public attitudes toward cancer pain.Cancer 56: 2337–2339Google Scholar
  73. Lindena G, Müller S, Zenz T (1994) Opioidverschreibung durch niedergelassene Ärzte. Schmerz 8: 228–234PubMedGoogle Scholar
  74. Ling GSFF, Spiegel K, Lockhart SH, Pasternak GW (1985) Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanism.J Pharmacol Exp Ther 232: 149–155Google Scholar
  75. Martin WR, Eades CG, Thompson JA (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog.J Pharmacol Exp Ther 197: 517–532Google Scholar
  76. McCaffery M (1983) Nursing the patient in pain. Harper and Row, LondonGoogle Scholar
  77. Mc Quay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236–244PubMedGoogle Scholar
  78. Melzack R (1986) Neurophysiological foundations of pain. In: Sternbach RA:The Psychology of Pain. Raven Press, New York, pp 1–24Google Scholar
  79. Mercadante S,Agnello A,Armata MG, Pumo S (1997)The inappropriate use of the epidural route in cancer pain. J Pain Symptom Manage 13: 233–237Google Scholar
  80. Miller R (1986) Midazolam as an adjunct to meperidine analgesia for postoperative pain.Clin J Pain 2: 37Google Scholar
  81. Moulin DE, Foley KM (1990) A review of a hospital-based pain service.In:Foley KM, Bonica JJ, Ventafridda V (eds) Advances in pain research and therapy. Raven Press, New York, pp 413–428Google Scholar
  82. O’Rourke K (1992) Pain Relief:The perspective of Catholic Tradition. J Pain Symptom Manage 7: 485–491PubMedGoogle Scholar
  83. Paul D, Standifier KM, Inturrisi CE, Pasternak GW (1989) Pharmacological characterization of morphine-6-glucuronide,a very potent morphine metabolite.J Pharmacol ExpTher 251: 477–483Google Scholar
  84. Paul D, Pick CG,Tive LA, Pasternak GW (1991) Pharmacological characterization of nalorphine, a kappa3 analgesic. J Pharmacol Exp Ther 257: 1–7Google Scholar
  85. Pert CB, Snyder SH (1973) Opiate receptor: demonstration in nervous tissue.Science 179: 1011Google Scholar
  86. Piletta P, Porchet HC, Dayer P (1991) Central analgesic effect of acetaminophene but not of aspirin. Clin Pharm Ther 49: 350–354Google Scholar
  87. Portenoy RK (1993) Cancer pain management. Sem Oncol 2 [Suppl 1]: 19–35Google Scholar
  88. Portenoy RK, Moulin DE, Rogers A, Inturrisi CE, Foley KM (1985) Intravenous infusion of opioids in cancer pain: Clinical review and guidelines for use. Cancer Treat Rep 70: 575–581Google Scholar
  89. Portenoy RK, Foley KM, Stulman J (1991) Plasma morphine and morphine6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 47: 13–19PubMedGoogle Scholar
  90. Portenoy RK,Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM (1992) The metabolite, morphine-6-glucuronide, contributes to the analgesia produced by morphine infusion in pain patients with normal renal function. Clin Pharmacol Therap 51: 422–431Google Scholar
  91. Principles of analgesic use in the treatment of acute pain and chronic cancer pain (1989) A concise guide to medical practice.2nd ed.Skokie, III.: American Pa in SocietyGoogle Scholar
  92. Ripamonti C,Bruera E (1991) Rectal, buccal,and sublingual narcotics for the management of cancer pain.J Palliat Care 7: 30–35Google Scholar
  93. Rogers M, Cerda JJ (1989) The narcotic bowel syndrome. J Clin Gastroenterol 11: 132–135PubMedGoogle Scholar
  94. Roy D (1990) Need they sleep before they die. J Palliat Care 6: 3–4Google Scholar
  95. Seff LB, Cuccherini BA, Zimmermann HI, Adler E, Benjamin SB (1986) Acetaminophene hepatotoxicity in alcoholics. Ann Int Medicine 104: 399–404Google Scholar
  96. Simon EJ, Hiller JM, Edelman I (1973) Stereospecific binding of the potent narcotic analgesic [3H]-etorphine to rat-brain homogenate. Proc Natl Acad Sci US 70: 1947–1949Google Scholar
  97. Singh PN, Sharma P, Gupta PK, Panday K (1981) Clinical evaluation of diazepam for relief of postoperative pain. Br J Anesth 53: 831Google Scholar
  98. Sorge J, Lüders B, Werry C, Pichlmayr I (1996) Die Versorgung von ambulanten Tumorpatienten mit Opioidanalgetika. Schmerz 10: 283–291PubMedGoogle Scholar
  99. Stein C (1993) Peripheral mechanisms ofopioid analgesia.Anesth Analg 76: 182–191Google Scholar
  100. Sunshine A, Olson NZ (1988) Analgesic efficacy of ketoprofene in postpartum, general surgery and chronic cancer pain. J Clin Pharmacol 28: 47–54Google Scholar
  101. Sverdlow M,Cundill JG (1981) Anticonvulsant drugs used in the treatment of lancinating pain. A comparison. Anesthesia 36: 1129Google Scholar
  102. Sykes NP (1991) Oral naloxone in opioid-associated constipation. Lancet II: 1475Google Scholar
  103. Tannock I, Gospdarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic prostatic cancer with low-dose prednisone:evaluation of pain and quality of life as pragmatic indices of response.J Clin Oncol 7: 590Google Scholar
  104. Terenius L (1973) Characteristics of the„receptor“for narcotic analgesics in synaptic plasma membrane fractions from rat brain. Acta Pharmacol Toxicol Kopenh 33: 377–384Google Scholar
  105. Twycross RG (1974) Clinical experience with diamorphine in advanced malignant disease. Int J Pharmacol Therap Toxicol 9: 184–198Google Scholar
  106. Twycross RG (1984) Relief of pain. In: Saunders C (ed) The Management of Terminal Malignant Disease. Edward Arnold, London, pp 64–90Google Scholar
  107. Twycross RG (1995) Therapeutics in terminal cancer, 3rd edn. RadcliffeMedical Press, OxfordGoogle Scholar
  108. Twycross RG, Ventafridda V (1979) Non-narcotic corticosteroid and psychotropic drugs in the continuing care of terminal cancer patients. In: Proceedings of an international seminar on continuing care of terminal cancer patients. Pergamon Press, New YorkGoogle Scholar
  109. Twycross RG, Fairfield S (1982) Pain in far-advanced cancer. Pain 14: 303–310PubMedGoogle Scholar
  110. Twycross RG, Lack SA (1983) Pain–a broader concept. In: Symptom Control in far advanced cancer. Pitman, London, pp 49–55Google Scholar
  111. Twycross RG (1998) Opioid analgesics in cancer pain:current practice and controversies. Cancer Surveys 7: 29–51Google Scholar
  112. Ulsenheimer K (1999) Arzt und Drogenwesen. In: Laufs A, Uhlenbruck W (Hrsg) Handbuch des Arztrechts.C.H. Beck, München 1079–1084Google Scholar
  113. Van Holten-Verzantvoort ATM,Zwinderman AH,Aaronson RK (1991)The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544–549Google Scholar
  114. Ventafridda V, Fochi C, DeConno F, Sganzerla E (1980) Use of NSAIDs in the treatment of pain in cancer. Br J Clin Pharmacol 10: 343–346Google Scholar
  115. Ventafridda V,Tamburini M, DeConno F (1985) Comprehensive treatment of cancer pain.ln:Fields HL,Dubner R,Cervero F (eds) Advances in pain research and therapy. Raven Press, New York, pp 617–628Google Scholar
  116. Ventafridda V,Tamburini M,Caraceni A, DeConno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59: 850–856Google Scholar
  117. VentafriddaV,Bianchi M, Ripamonti C,Sacerdote P,DeConno F,Zecca R,Paneari AE (1990a) Studies on the effects of antidepressant drugs on the antinoceptive action of morphine and on plasma morphine in rat and man. Pain 43: 155–162Google Scholar
  118. Ventafridda V, Ripamonti C, DeConno F, Tamburini M (1990b) Symptom prevalence and control during cancer patients’ last days of life. J Palli-at Care 6: 7–11Google Scholar
  119. Wallenstein SL (1975) Analgesic studies of aspirin in cancer patients. Proceedings of the aspirin symposium. Aspirin Foundation, London, p 5Google Scholar
  120. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 55: 569–580PubMedGoogle Scholar
  121. Walsh TD (1990) Prevention of opioid side effects.J Pain Symptom Manage 5: 362–367Google Scholar
  122. Ward SE, Goldberg N, Miller-McCauley V et al. (1993) Patient-related barriers to management of cancer pain. Pain 52: 319–324PubMedGoogle Scholar
  123. Watanabe S, Belize M, Kuehn N (1996) Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Clinical and economic considerations.Cancer Treat Rev 22: 131–136Google Scholar
  124. Waugh L (1988) Psychological aspects of cancer pain. Professional Nurse 9: 504–508Google Scholar
  125. Weissman DE (1988) Glucosteroid therapy for brain metastases and epidural spinal cord compression:a review.J Clin Oncol 6: 543Google Scholar
  126. Weissman DE (1996) Cancer pain education for physicians in practice: es- tablishing a new paradigm.J Pain Symptom Manage 12: 364–371Google Scholar
  127. Weissman DE, Dahl JL (1990) Attitudes about cancer pain: a survey of Wisconsin’s first-year medical students. J Pain Symptom Manage 5: 345–349PubMedGoogle Scholar
  128. Willer IC, DeBrouckertT, Bussel B, Robi-Brauni A, Harrewyn JM (1989) Central analgesic effect of ketoprofen in humans: electrophysiologic evidence for a supraspinal mechanism in a double blind and crossover study. Pain 38: 1–7Google Scholar
  129. Willcox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M (1984) Prednisolone as appetite stimulant in patients with cancer pain. Br Med J 288: 27Google Scholar
  130. World Health Organization (1996) Cancer pain relief,2nd edn.WHO, GenevaGoogle Scholar
  131. Yamada K, Ushio Y, Hayakawa T, Kato A, Arita N, Yamada N (1983) Effects of methylprednisolone on peritumoral brain edema.J Neurosurg 59: 612Google Scholar
  132. Zagon IS, Gibo DM, McLaughlin PI (1991) Zeta (),a growth-related opioid receptor in developing rat cerebellum: identification and characterization. Brain Res 551: 28–35PubMedGoogle Scholar
  133. Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA (1995) Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain 63: 65–76PubMedGoogle Scholar
  134. Zenz M (1993) Neues und Bewährtes in der medikamentösen Behandlung des chronischen Schmerzes.Schmerz [Suppl] 5: 52Google Scholar
  135. Zenz M, Willweber-Strumpf A (1993) Opiophobia and cancer pain in Europe. Lancet 341: 1075–1076PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • B. Fazeny-Dörner
  • C. Dittrich

There are no affiliations available

Personalised recommendations